Compounds > atrasentan
Page last updated: 2024-09-04

atrasentan and Diabetic Angiopathies

atrasentan has been researched along with Diabetic Angiopathies in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (50.00)29.6817
2010's2 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Andress, DL; Bakris, G; Brennan, JJ; Correa-Rotter, R; de Zeeuw, D; Heerspink, HJL; Hou, FF; Kitzman, DW; Kohan, D; Makino, H; McMurray, J; Parving, HH; Perkovic, V; Tobe, S; Wigderson, M; Yi, T1
Ergul, A; Li, W; Sachidanandam, K1
Banes-Berceli, AK; Ketsawatsomkron, P; Marrero, MB; Ogbi, S; Patel, B; Pollock, DM1
Elgebaly, MM; Ergul, A; Harris, AK; Hutchinson, JR; Mezzetti, EM; Portik-Dobos, V; Sachidanandam, K1

Trials

1 trial(s) available for atrasentan and Diabetic Angiopathies

ArticleYear
Baseline characteristics and enrichment results from the SONAR trial.
    Diabetes, obesity & metabolism, 2018, Volume: 20, Issue:8

    Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atrasentan; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Diuretics; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Endothelin A Receptor Antagonists; Female; Glomerular Filtration Rate; Humans; Hypertension; Male; Middle Aged; Precision Medicine; Renal Insufficiency; Risk

2018

Other Studies

3 other study(ies) available for atrasentan and Diabetic Angiopathies

ArticleYear
Comparison of selective versus dual endothelin receptor antagonism on cerebrovascular dysfunction in diabetes.
    Neurological research, 2011, Volume: 33, Issue:2

    Topics: Animals; Atrasentan; Bosentan; Cerebral Arteries; Cerebrovascular Circulation; Cerebrovascular Disorders; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Male; Pyrrolidines; Rats; Rats, Inbred Strains; Receptor, Endothelin A; Receptor, Endothelin B; Sulfonamides; Vasodilator Agents

2011
Angiotensin II and endothelin-1 augment the vascular complications of diabetes via JAK2 activation.
    American journal of physiology. Heart and circulatory physiology, 2007, Volume: 293, Issue:2

    Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Atrasentan; Benzimidazoles; Biphenyl Compounds; Blood Glucose; Blood Pressure; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Endothelin A Receptor Antagonists; Endothelin-1; Enzyme Activation; Intracellular Signaling Peptides and Proteins; Janus Kinase 2; Male; Phosphorylation; Protein Kinase Inhibitors; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Protein Tyrosine Phosphatases; Pyrrolidines; Rats; Receptor, Angiotensin, Type 1; Receptor, Endothelin A; Signal Transduction; STAT1 Transcription Factor; STAT3 Transcription Factor; Tetrazoles; Time Factors; Tyrphostins; Vasodilation

2007
Effect of chronic and selective endothelin receptor antagonism on microvascular function in type 2 diabetes.
    American journal of physiology. Heart and circulatory physiology, 2008, Volume: 294, Issue:6

    Topics: Acetylcholine; Animals; Atrasentan; Cardiovascular Agents; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Male; Mesenteric Arteries; Microcirculation; Myography; Peptides, Cyclic; Pyrrolidines; Rats; Rats, Wistar; Receptor, Endothelin A; Receptor, Endothelin B; Up-Regulation; Vasoconstriction; Vasoconstrictor Agents; Vasodilation; Vasodilator Agents; Viper Venoms

2008